Here are the Form 4 insider transactions from Beyond Air, Inc. (XAIR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XAIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAIR filings page.
Beyond Air, Inc. (XAIR) ten percent owner Lin Yi-Chien purchased 2,607 shares of common stock on October 13, 2026, at $2.21 per share. The transaction was reported as a direct purchase; reported direct holdings after it were 148,000 shares. No Rule 10b5-1 plan is reported.
Beyond Air, Inc. (XAIR) ten percent owner Lin Yi-Chien reported three direct purchases totaling 20,393 shares of common stock: 15,393 on October 1, 2026, at a $2.80 weighted-average price; 2,000 on September 30 at $2.71; and 3,000 on September 29 at $2.69. Each reported price is a weighted average; the underlying purchases were at prices ranging from $2.67 to $2.85, inclusive. No Rule 10b5-1 plan is reported.
Beyond Air, Inc. Chief Executive Officer Robert Scott Goodman purchased 34,722 shares of common stock on July 29, 2026 at $5.76 per share, bringing his direct common stock holdings to 34,822 shares. He also acquired 34,722 Series A Warrants and 34,722 Series B Warrants, each exercisable for common stock at $5.51 per share. The warrants are exercisable immediately; the Series A Warrants expire on the earlier of one year after issuance or 45 days following FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance.
Beyond Air, Inc. Chief Financial Officer Daniel J. Moorhead reported purchases on 2026-07-29 of 4,340 shares of common stock at $5.76 per share, along with 4,340 Series A Warrants and 4,340 Series B Warrants, each exercisable for common stock at $5.51 per share. The Series A Warrants are exercisable immediately and expire on the earlier of one year from issuance or 45 days after FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance. Following these transactions, Moorhead holds 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants directly.
Beyond Air, Inc. granted its Chief Financial Officer, Daniel J. Moorhead, a new stock option award. On January 5, 2026, he received an inducement grant of options to buy 70,000 shares of common stock at an exercise price of $0.79 per share, matching the closing price on January 2, 2026. The options expire on January 4, 2036.
According to the vesting terms, 25% of the options vest on the one-year anniversary of January 5, 2026, and the remaining 75% vest in three equal annual installments after that, as long as he remains employed. Any portion that is unexercisable when his employment ends will not become exercisable later. After this grant, he beneficially owns 70,000 stock options directly.
Beyond Air, Inc. (XAIR) reported an insider equity change for a director on Form 4. On November 4, 2025, the Board approved an option repricing effective that same day, reducing the exercise price of multiple stock option grants to $1.95 per share, which matches the closing price of Beyond Air’s common stock on November 3, 2025.
The filing shows that previously granted stock options with higher exercise prices, including options priced at $10.80 and $5.892 per share, were adjusted to the new $1.95 level. All other terms of the options, such as the number of underlying shares and expiration dates, remain unchanged.
The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan. They continue to vest according to the original vesting schedules set out in the award agreements, contingent on the reporting person’s continued service with Beyond Air on the applicable vesting dates.
Beyond Air, Inc. (XAIR) filed a Form 4 reporting that its Chief Operating Officer had existing stock options repriced. On November 4, 2025, the Board of Directors approved an option repricing, effective the same day, reducing the exercise price of several option grants to $1.95 per share, which was the closing price of Beyond Air’s common stock on November 3, 2025. All other terms of the options, including the number of shares and expiration details, remain unchanged.
The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan. They become exercisable based on the vesting schedule in the original award agreements, which continue to require the reporting person’s ongoing service with the company on each vesting date.